ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months. Read More “ITL Achieves Record Month”
ITL News & Events
ITL Limited Rebrands to ITL Health Group to Unify Divisions under a Global Brand
ITL Limited (ASX:ITD), an innovative global medical technology company, supplier and strategic partner that provides innovative products and solutions to healthcare markets and empowers individual health management, formally announces its rebrand to ITL Health Group (ITL).
Read More “ITL Limited Rebrands to ITL Health Group to Unify Divisions under a Global Brand”
ITL Half Year Results and BioMedical Growth Update
Following the strong first half results announced on Friday 17th February the company is issuing the following presentation – “Half year results 2016/17 and ITL BioMedical Growth Update” – in order to provide greater insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
Read More “ITL Half Year Results and BioMedical Growth Update”
Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update
ITL Limited is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.
Mr Mobbs talks about the Company’s strong first half results that saw revenue rise 11%, EBITDA up 69% and profit before tax grow 110% versus the previous comparative period, and provides an insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
Read More “Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update”
ITL Profit Doubles in Half Year 2016-17 Results
ITL Limited (“ITL”), an innovative diversified healthcare company, is pleased to announce excellent results for the half year ended 31 December 2016 compared with the previous corresponding period.
ITL brings on Specialist Small Cap Fund Manager
Founder and Executive Chairman Mr. Bill Mobbs has released a parcel of his 42% of ITL (4.6m shares) to a Specialist Small Cap Fund Manager and to fellow ITL non-executive Director Mr. Mark Peatey. Mr. Mobbs retains 36% of ITL.
ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2
ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare® Needle Guard 2 will take place at the AABB Annual Meeting in Orlando, the premiere event for healthcare professionals in transfusion medicine and cellular therapies. Read More “ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2”
ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux
ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries. Read More “ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux”
5 Year Contract Win with Macquarie University Hospital
ITL Limited, a diversified healthcare company and owner of ITL Healthcare which produces quality invasive blood pressure monitoring systems, is pleased to announce a new five year contract with Macquarie University Hospital (MUH), Australia’s first private not-for-profit teaching hospital, located at Macquarie University in Sydney. Read More “5 Year Contract Win with Macquarie University Hospital”
